Recent studies have clearly shown that long-range, three-dimensional chromatin looping interactions play a significant role in the regulation of gene expression, but whether looping is responsible for or a result of alterations in gene expression is still unknown. Until recently, how chromatin looping affects the regulation of gene activity and cellular function has been relatively ambiguous, and limitations in existing methods to manipulate these structures prevented in-depth exploration of these interactions. To resolve this uncertainty, we engineered a method for selective and reversible chromatin loop re-organization using CRISPR-dCas9 (CLOuD9). The dynamism of the CLOuD9 system has been demonstrated by successful localization of CLOuD9 constructs to target genomic loci to modulate local chromatin conformation. Importantly, the ability to reverse the induced contact and restore the endogenous chromatin conformation has also been confirmed. Modulation of gene expression with this method establishes the capacity to regulate cellular gene expression and underscores the great potential for applications of this technology in creating stable de novo chromatin loops that markedly affect gene expression in the contexts of cancer and development.
Introduction
The relationship between chromatin folding in the nucleus and the specific organization of the genome has garnered significant interest in recent years, as it has been shown to be closely associated with gene expression 1, 2 . While the precise relationship between gene activity and modulation of chromatin structure remains unclear, it has been hypothesized that the interactions between chromosomal contacts as a result of dynamic three-dimensional chromatin organization serve a gene regulatory function 3 . Indeed, such an effect has been well demonstrated at the human globin gene locus, where the locus control region (LCR) regulates the activity of the globin genes in a developmentally specific manner by creating a chromatin loop between the two regions 4 . However, in both this and other regions, it is unclear whether chromatin looping is a cause or consequence of alterations in gene expression.
Until now, the challenges in studying this phenomenon remained unresolved. For example, other attempts at inducing chromatin loops involved modifying the linear DNA sequence or complicated procedures requiring an abundance of background knowledge on specific elements that facilitate looping 5, 6, 7, 8 . Additionally, while previous work has suggested that chromatin loops drive gene expression in a specific and restricted context 7, 8 , the level at which chromatin looping affects transcription globally is uncertain. Though interest in the impact of long-range looping on gene expression has grown continually in recent years, unanswered questions about establishing and retaining chromatin contacts to change gene activity persist.
Lentivirus Transduction of Cells
1. Add 250 µL of each viral construct of interest (comprised of complementary CLOuD9 plasmids) to a 15 mL conical tube containing 80,000 cells for the CLOuD9 application. 2. Bring the total volume of media in each conical to 1 mL with antibiotic-free media, and add polybrene to a final concentration of between 1-8 µg/mL (the maximum concentration of polybrene tolerated by the cell type utilized will need to be determined experimentally). 3. Spin cells at 800 x g for 30 min at room temperature, then resuspend by pipetting without removing the viral supernatant. Move the entire cell suspension to a cell culture plate. 4. 24 h post-transduction, spin cells down at 300 x g for 5 min at room temperature. 5. Aspirate viral supernatant and resuspend cells in regular cell culture media. 6. On the next day, add puromycin (1 µg/mL for 293T cells) and hygromycin (25 µg/mL for 293T cells) to the cell culture medium to select for doubly transduced cells. Experimentally determine the appropriate concentrations of puromycin and hygromycin for a given cell type prior to beginning the experiments. 7. Keep cells in selection media for at least 3 d before any downstream experiments and maintain in selection media for the duration of all experiments. Transfer an appropriate amount of beads for the experiment to a 1.5 mL tube. As a starting point, use 20 µL of beads for every 1 µg of antibody. Do not add antibody yet. NOTE: Use 10 µg antibody with 200 µL of beads for 1 mg of total lysate as a starting point, unless it is known that the antibody is more or less efficient than this would imply. For low abundance proteins, this ratio may need to be adjusted. 3. If using Farnham lysis buffer, wash 3x in IP dilution buffer. If using RIPA lysis buffer, wash 3x in RIPA lysis buffer. 4. Resuspend beads in a final volume of the same buffer from step 7.3.3 (either IP dilution or RIPA buffer) that is >1x and <5x the initial volume. i.e. For 100 µL initial bead volume, use between 100 and 500 µL final resuspension volume. 5. Add antibody to washed beads now at an appropriate concentration. For a good HA or Flag antibody to IP CLOuD9 constructs, use antibodies at 1:50 (µg protein: µg protein lysate) and incubate between 8+ h and overnight at 4 °C, while rotating. Alternatively, incubate for 2-4 h at room temperature. 6. Remove the supernatant from beads and discard. 3. Then spin nuclei down at 4 °C for 5 min at 1,500 x g. Aspirate the supernatant completely and repeat to remove remaining supernatant, then weigh the cell pellet in mg. 4. Add protease inhibitor to nuclei lysis buffer (Farnham buffer or RIPA buffer, above, choose one). 5. Add 10x amount of nuclei lysis buffer to pelleted nuclei to resuspend (for example, add 1 mL of nuclei lysis buffer to a 0.100 g pellet).
Cell Dimerization and Wash Out
Briefly vortex and lyse for 10 min on ice. NOTE: Keep in mind the size of the sonication tube. Ideal volume is often <1 mL, so samples may need to be divided if pellets are very large.
1. For Co-IP, sonicate nuclei briefly to solubilize material and quench SDS to a level that permits immunoprecipitation with 2-3 volumes of dilution buffer, then proceed to step 7.4.6. For very sensitive antibodies, add more dilution buffer to further reduce the concentration of SDS. NOTE: Stop sonication when lysate clears; it will change from an opaque/translucent white to completely transparent. Keep samples as cold as possible and do not over sonicate. 2. For ChIP, thoroughly sonicate DNA to obtain 150-1000 bp DNA fragments, then proceed to step 7.4.6.
6. Spin out insoluble material at maximum speed for 10 min at 4 °C. 7. Transfer soluble material to a fresh tube. 8. For Co-IP, measure the concentration of protein and proceed to the pulldown in step 7.5. 9. For ChIP, remove a 10 µL aliquot of cleared lysate and add 40 µL IP elution buffer and 6 µL 5 M NaCl to that for a total of 56ul. Boil for 15 min at 95 °C, add 5-10 µL of 3 M NaOAc pH 5, and clean up on a PCR purification column. Measure the concentration of DNA by measuring the absorbance at 260 nm and standardize across samples. Then proceed to pulldown in step 7.5. NOTE: Extra lysate can be snap frozen at -80 °C and used at a later time, but best results are obtained from the fresh lysate. If freezing, do not freeze/thaw lysate more than once. Prior to induction of dimerization, chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) was utilized to ensure accurate localization and targeting of each CLOuD9 component (Supplementary Figure 1) . Additionally, co-immunoprecipitation (Co-IP) with and without ABA verified CSA and CSP dimerization in the presence of the ligand as well as reversibility in the absence of the ligand (Figure 1c and Supplementary  Figure 2) . 24 h after adding ABA, greater contact between β-globin and the LCR appeared as measured by chromosome conformation capture (3C) in the cells with both dimerization parts, but not the controls containing only two CSA or CSP constructs, thus validating the specificity of the chromatin change for the targeted sites (Figure 1c and Supplementary Figures 3,4) . Creating the LCR-β-globin interaction did not completely eliminate the endogenous LCR-globin contact, but instead, added to the original contact, as previously reported 8 . Increases in β-globin/LCR contacts were observed for up to 72 h of dimerization, regardless of the exact region within the targeted LCR and β-globin promoter region (Supplementary Figures 5,6) . Lastly, the reversibility of the system was confirmed with 3C after removing ABA, which showed a complete renewal of the endogenous conformation (Figure 1d and Supplementary Figures 3-6 ).
We considered that the success shown in the K562 cells may be a result of the globin locus location in a region of euchromatin (Figure 1d) , so a second cell line was utilized to explore this idea. The CLOuD9 system was applied to HEK 293T cells in regions that are heterochromatic and do not express globin genes (Figure 1e) . The result was similar to what was observed in K562s; more β-globin LCR associations were measured by 3C after 24 h with ABA (Figure 1e and Supplementary Figure 3) , providing evidence for CLOuD9's robust ability to function in different cellular environments, despite the original chromatin state or conformation.
Additional loci were tested to ensure the broad applicability of CLOuD9, including the Oct4 promoter and a distal 5' enhancer within 293T cells. Previously, there has been no detectable Oct4 expression in this cell line and further, no endogenous contacts described. Evidence of Oct4 expression in embryonic stem cells resulting from contact with the distal 5' enhancer motivated this experiment, and the same outcome was observed at the β-globin locus 18 . Contact between the Oct4 distal enhancer and promoter was identified in the CLOuD9 enabled cells, but not the control cells (Figure 1f) . Additionally, it was observed that the Oct4 promoter and distal 5' enhancer interaction also prompted a 3' enhancer to contact the Oct4 promoter. This event is consistent with evidence that the 3' enhancer interacts with the Oct4 promoter/5' distal enhancer complex during endogenous gene activation 10 .
CLOuD9 induces context specific alterations at gene loci. After confirming that the CLOuD9 system does indeed induce chromosomal contacts at gene loci, we sought to examine the loops' effect on gene expression. It has been documented that transcription for the globin and Oct4 genes are contingent on the contacts between the LCR and globin gene loci and between the distal 5' enhancer and Oct4 promoter, respectively 1, 11 . Thus, we hypothesized that using the CLOuD9 system to drive chromatin loop formation in each of these regions would result in compelling gene expression.
In both loci, RT-qPCR demonstrated that ABA induced chromatin loops drove increases in Oct4 expression in 293T cells, and in β-globin expression in K562 cells, though not in 293Ts (Figure 2a) . Though the addition of ABA to cell culture for as little as 24 h increased β-globin expression significantly, expression continued to increase steadily up to 72 hours and was reversible upon ABA washout (Figure 2a) . All of the K562 cells except for the controls followed this trend, no matter where the dimerization components were located in the LCR and β-globin promoter regions (Figure 2a and Supplementary Figures 7,8) . In support of these findings, ChIP-qPCR of H3K4me3 and RNA Pol-II at the β-globin locus in K562s and 293Ts corresponded with observed alterations in transcription (Figure 2c-f ). robust pair for experimental purposes. Further, in each pair of target regions, the CSA construct should be targeted with gRNAs for S. aureus, and the CSP construct should be targeted with gRNAs for S. pyogenes for targeting specificity.
To ensure accurate results and correct dimerization, it is also important to maintain the freshness of the cellular environments following the transduction of the CLOuD9 constructs. Daily media change and the addition of fresh dimerizer (or control) ensures that the complementary constructs will remain in proximity and preserve the altered chromatin conformation. Furthermore, guaranteeing the ABA is fresh and has been stored appropriately according to the manufacturer's protocol (opened within 6 months, kept cold, protected from light) is essential to obtaining authentic results.
Notably, the ABA dimerizer for CLOuD9 was used with the ABI and PYL dimerization proteins, rather than the more commonly utilized FRB and FKBP system. The necessity of a rapalog for the FRB/FKBP system would have limited the applicability of CLOuD9, due to the toxicity to cancer cells. The alternative ABI/PYL system circumvented this limitation, effectively enabling CLOuD9 to be more broadly utilizable.
Collectively, we have developed CLOuD9, a unique and robust technology that can forcibly but reversibly create contacts between long-range target genomic loci. Through inducing chromatin loops, we also demonstrate that CLOuD9 can be utilized to modify gene expression in the appropriate cellular context. The adaptability of the technology allows for the unrestricted study of the interactions between any two genomic loci, without requiring prior knowledge of the looping regions or looping mechanisms. In addition, CLOuD9's unique demonstrated reversibility enables further examination of the looping mechanisms in disease and development. While the on-target effects of chromatin looping have been demonstrated clearly, there is yet to be data offering insight into the effects of off-target looping and the subsequent impact on the on-target loops.
Our data illustrates only a few applications of this tool but implies the major underlying idea that chromatin arrangement is indicative of gene expression. Our technology can be used to study and reveal the nuances of chromatin structure in gene regulation, thereby improving the overall comprehension of the role of chromatin folding in transcription of genes. A better understanding of the subtleties of transcriptional dynamics can lead the way in research and treatment of cancer, hereditary diseases, and congenital disorders, in which distinct chromatin assembly undoubtedly alters gene expression 20, 21, 22, 23 . Subsequent work utilizing the CLOuD9 technology will illuminate further details about the arrangement and dynamics of chromatin domains and how they drive folding to sustain stable gene expression in both development and disease.
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